Camel milk in asthmatic children: a double blind randomized clinical trial

Elham Bakhtiari
Mashhad University of Medical Sciences

Soudabeh Nekouhi
Mashhad University of Medical Sciences

Saeid Zibaee
Razi Vaccine and Serum Research Institute

Hasan Rakhshandeh
Mashhad University of Medical Sciences

Seyed Javad Sayedi (✉ Sayedij@mums.ac.ir)
Mashhad University of Medical Sciences, Mashhad, Iran

Research Article

Keywords: camel milk, child, randomized clinical trial, asthma

Posted Date: March 11th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-269628/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Asthma is one of the prevalent diseases in children. There is some evidence regarding benefits of camel milk in asthma. Present study was carried out evaluating the effect of camel milk in asthmatic children. A randomized double blind clinical trial was operated between 2018 and 2019 in a tertiary center. Sixty children aged more than 6 years with not well control asthma were included. Intervention was consist of 200 milliliter camel milk or placebo daily for 2 months. Spirometry parameters and medication regimen were assessed before and after intervention. Data was analyzed using SPSS software. A total of 57 patients completed the trial. Patients were similar in demographic and baseline characteristics (p > 0.05). There was a significant difference between groups after intervention in use of inhaled corticosteroids (96.7% versus 70.4%, p value = 0.01), short acting beta agonists (53.3% versus 29.6%, p value = 0.0001) and long acting beta agonists (53.3% versus 40.7%, p value = 0.04) in control and intervention respectively. The percent of changes in forced expiratory volume (FEV1) in control and intervention groups was 18.54 ± 14.89 and 21.89 ± 17.83 respectively (p = 0.14). The percent of changes in FEV1/forced vital capacity (FVC) in control and intervention groups was 8.11 ± 7.12 and 11.11 ± 8.33 respectively (p = 0.14).

Conclusion: Camel milk leads to significant decrease in inhaled corticosteroids, short acting beta agonists and long acting beta agonist's use, surprisingly. It was suggested that camel milk is added to pharmacological treatment of asthmatic children after more studies.

What Is Known

- In many children the good control of asthma not achieved with the chemical medications.
- Compliance of chemical medications are lower in children compared to adults

What is new?

- The effect of camel milk in asthmatic children was studied for the first time
- Camel milk leads to decrease in inhaled corticosteroids, short acting beta agonists and long acting beta agonist's use, significantly

Introduction:

Asthma is one of the common chronic inflammatory diseases during childhood with the prevalence of 15% (1). It characterized by wheeze, shortness of breath, cough and many other symptoms leading to economic burdens, psychological disorders and decreased quality of life (2). In many patients the good control of asthma not achieved with the chemical medications. On other hand compliance of chemical medications are lower in children compared to adults (3). World Health Organization (WHO)
recommended people to use natural products especially in developing countries, because of generally low price, less side effects as well as more compliance (4).

Benefit properties of camel milk been reported in several studies. It consist of antidiabetic (5, 6), anti-hyperlipidemia (5, 7), improvement of autistic behavior (8, 9) and many other reports (10–12). There is some evidence that camel milk has anti-inflammatory effects (13–15). But there is not any randomized clinical trial (RCT) evaluating the effect of camel milk in children with asthma.

To offer new insight, present double blind randomized clinical study was carried out, evaluating the effect of 200 milliliter (ml) camel milk daily for 2 months on asthmatic children aged more than 6 years.

**Patients And Methods:**

Present study was a double blind randomized clinical trial. It was done between 2018 and 2019 in a tertiary center, Mashhad University of Medical Sciences, Mashhad, Iran. The study population were children aged more than 6 years with a not well controlled asthma according to nelson reference book and have forced expiratory volume (FEV1) between 60%-80% and FEV1/ forced vital capacity (FVC) between 75%-80% in primary spirometry.

This study was approved in medical ethics committee (code: IR.MUMS.fm.REC.1396.555) and registered in Iranian registry of clinical trials (IRCT) (code: IRCT20170813035653N2).

Following written parental consent, combined with patient consent in appropriate cases, 60 children (age range: 6–18 years) with approved asthma were included. All clinical examination was done by one pediatrics pulmonologist. Patients were excluded if they have an asthma attack during study. Consort flowchart of study is shown in Fig. 1. Intervention was consist of 200 ml pasteurized camel milk daily for 2 months. Cow milk was considered as placebo and was packaged as same as camel milk. Spirometry was performed using CHEST HI-801 device (Japan).

Randomization was based on computer generated random sequence. Allocation concealment was done via sealed envelope. Primary outcomes were evaluated by an expert who was not involved in the study. Thirty patients in each group (totally 60 patients) were considered appropriate according to 20% detectable change between control and intervention group according to an expert opinion.

**Statistical analysis**

Data was analyzed using SPSS 16 (SPSS Inc, Chicago, Illinois, United States). Association of qualitative variables was tested by Fisher exact test or Chi square. Quantitative variables were compared using independent-samples T test. A p value less than 0.05 was considered statistically significant.

**Results:**

**Baseline characteristics**
Among 60 enrolled patients, 57 patients completed the study included 30 patients in control group and 27 ones in intervention group. Nineteen patients (63.3%) and 20 patients (74.1%) were male in control and intervention group respectively (p = 0.28). The mean age of patients in control and intervention group was $11.4 \pm 2.31$ and $9.74 \pm 2.67$ years respectively (p = 0.08). FEV1 was $70.23 \pm 8.64$ and $74.23 \pm 8.10$ percent in control and intervention group respectively. FEV1/FVC was $78.9 \pm 2.92$ and $79.3 \pm 3.51$ percent in control and intervention group respectively (p > 0.05). Inhaled corticosteroids (ICS), short acting beta agonists (SABA) and long acting beta agonists (LABA) were the most common medications in control and intervention group (p > 0.05). Totally patients were similar in demographic and baseline characteristics. Data is presented in Table 1.

| variables          | Intervention group (n = 27) Mean ± SD/frequency (%) | Control group (n = 30) Mean ± SD/frequency (%) | P value |
|--------------------|-----------------------------------------------------|-----------------------------------------------|---------|
| Age (year)         | 9.74 ± 2.67                                         | 11.4 ± 2.31                                   | 0.08*   |
| Sex (%)            | 20 (74.1%)                                          | 19 (63.3%)                                    | 0.25#   |
| Male               | 7 (25.1%)                                           | 11 (36.7%)                                    |         |
| female             |                                                     |                                               |         |
| FEV1 (%)           | 74.23 ± 8.10                                        | 70.23 ± 8.64                                  | 0.07*   |
| FEV1/FVC           | 79.3 ± 3.51                                         | 78.9 ± 2.92                                   | 0.64*   |
| ICS                | 26 (96.3%)                                          | 30 (100%)                                     | 0.47#   |
| SABA               | 21 (77.8%)                                          | 20 (66.7%)                                    | 0.29#   |
| LABA               | 17 (56.7%)                                          | 16 (59.3%)                                    | 0.99#   |
| Oral corticosteroids | 1 (3.7%)                                         | 3 (10%)                                       | 0.61#   |
| Other drugs        | 9 (33.3%)                                           | 15 (50%)                                      | 0.28#   |

SD = standard deviation, FEV1 = FEV1 = forced expiratory volume, FVC = forced vital capacity, ICS = inhaled corticosteroids, SABA = short act beta agonist, LABA = long act beta agonist *Independent t test, # chi square test or fisher exact test

**Spirometry parameters and medications**

After 2 months, the FEV1 in control and intervention group was $84.73 \pm 10.35$ and $88.20 \pm 15.80$ respectively. The FEV1/FVC in control and intervention group was $85.20 \pm 4.87$ and $88.04 \pm 6.95$
respectively. The percent of changes in spirometry parameters was not significant between groups. Data is presented in Table 2.

| variables                     | Intervention group (n = 27) Mean ± SD/frequency (%) | Control group (n = 30) Mean ± SD/frequency (%) | P value |
|-------------------------------|-----------------------------------------------------|------------------------------------------------|---------|
| Changes in FEV1 (%)           | 21.89 ± 17.83                                       | 18.54 ± 14.89                                    | 0.19*   |
| Changes in FEV1/FVC (%)       | 11.11 ± 8.33                                        | 8.11 ± 7.12                                      | 0.14*   |
| ICS                           | 19 (70.4%)                                          | 29 (96.7%)                                       | 0.01#   |
| SABA                          | 8 (29.6%)                                           | 16 (53.3%)                                       | 0.0001# |
| LABA                          | 11 (40.7%)                                          | 16 (53.3%)                                       | 0.04#   |
| Oral corticosteroids          | 0                                                  | 1 (3.3%)                                         | 0.99#   |
| Other drugs                   | 2 (7.4%)                                            | 7 (23.3%)                                        | 0.03#   |

SD = standard deviation, FEV1 = forced expiratory volume, FVC = forced vital capacity, ICS = inhaled corticosteroids, SABA = short act beta agonist, LABA = long act beta agonist *Independent t test, # chi square test or fisher exact test

There was a significant difference between groups in ICS use after intervention (96.7% versus 70.4% in control and intervention respectively, p value = 0.01). There was a significant difference between groups in SABA (53.3% versus 29.6% in control and intervention respectively, p value = 0.0001) and LABA (53.3% versus 40.7% in control and intervention respectively, p value = 0.04) use. There was a significant difference between groups in other drugs including montelukast, cetirizine and etc. (23.3% versus 7.4% in control and intervention respectively, p value = 0.039).

There was no significant difference between groups in oral corticosteroids (p = 0.99).

Data is presented in Table 2.

There was no asthma attack in control and intervention group during study. There was no adverse effect, to use of camel milk.

**Discussion:**

In a double blind randomized clinical trial, 57 children aged more than 6 years were studied evaluating the effect of camel milk in children with asthma. To the best of our knowledge, benefits of camel milk in asthmatic children was confirmed in present study for the first time. According to results, consumption of
ICS, SABA, LABA and other drugs significantly decreased in intervention group compared to control. Also the percent of changes of spirometry parameters was more in intervention group but not significantly.

The use of natural products was increased during last decades (16, 17). Camel milk was used extensively worldwide because of its therapeutics and preventive properties in several conditions including allergy (18), cancer (19), diabetes (5) and immune disorders (20). Because of increased use of camel milk, clinicians must be aware of its pharmacological properties. To the best of our knowledge present study is the first research demonstrating the efficacy of camel milk in asthmatic children. Clinical efficacy of camel milk in asthma was studied only in a RCT in adults by Ravaghi et al. (21). According to Ravaghi the changes in the mean of FEV1 significantly was higher in intervention group compared to control. In our study spirometry parameters did not change significantly. It may be due to our studied population which were children. There are some challenges in use of spirometry for children. Children may uptake the exact instruction of spirometry difficultly and may have less cooperation for procedure which affect the results.

Camel milk is different with other mammalian milks (22–24). It had more minerals and vitamins as well as antioxidants. In comparison with cow milk, camel milk has more whey protein including lactoferin and immunoglobulin G (IG) and other antibodies (25, 26). The relationship between IgG deficiency and asthma and allergy is recognized completely (27, 28). In attention to high content of IgG in camel milk, it can be used as a good option in children with asthma and food allergy. On the other hand asthma is an inflammatory disease. According to documents camel milk decrease tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), interleukin 6 (IL6), and interleukin 17 (IL17) (29, 30), therefore it can be effective in improvement of disease’s signs.

Anti-inflammatorv and immunomodulatory properties of camel milk were investigated in some experimental and clinical studies (15, 31, 32). In a study by Zhu et al. it has been demonstrated that camel milk can decrease TNF-α, IL1B and oxidative stress markers in mice with acute respiratory syndrome (33). Despite of several evidences regarding the anti-inflammatory, immunomodulatory and antioxidant properties of camel milk, more clinical trials are needed to confirm the traditional knowledge lead to comprehensive use of camel milk in asthmatic patients.

Due to the beneficial effects of camel milk in asthmatic children, further studies with larger sample sizes are suggested to examine the effects of camel milk in more detail.

Limitations:

Poor cooperation of children for spirometry was the main limitation of present study.

**Conclusion:**

Camel milk surprisingly leads to significant decrease in ICS, SABA, LABA and other drugs consumption and better general condition in asthmatic children. It was suggested that camel milk is added to
pharmacological treatment of asthmatic children after more studies.

**Abbreviations**

RCT: randomized clinical trial

WHO: World Health Organization

ML: milliliter

FEV1: forced expiratory volume

FVC: forced vital capacity

IRCT: *Iranian registry of clinical trials*

ICS: Inhaled corticosteroids

SABA: short acting beta agonists

LABA: and long acting beta agonists

IG: immunoglobulin G

TNF-α: tumor necrosis factor alpha

TGF-β: transforming growth factor beta

IL6: interleukin 6

IL 17: interleukin 17

**Declarations**

Funding: This work was financially supported by a research grant (Grant No.960478) from Mashhad University of Medical Sciences, Mashhad, Iran.

Conflicts of interest/Competing interests: The authors declare that there is no conflict of interest.

Availability of data and material: N/A

Code availability: N/A

Authors’ contributions:

Seyed Javad Sayedi, Elham Bakhtiari, Saeid Zibaee: conception or design
Elham Bakhtiari, Soudabeh Nekouhi, Saeid Zibaee, Hasan Rakhshandeh: acquisition, analysis

Elham Bakhtiari, Soudabeh Nekouhi, Saeid Zibaee, Hasan Rakhshandeh, Seyed Javad Sayedi: drafting the work

Elham Bakhtiari, Soudabeh Nekouhi, Saeid Zibaee, Hasan Rakhshandeh, Seyed Javad Sayedi: final approval

Ethics approval:

All procedures performed in studies including human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Present study was approved by Mashhad University of Medical Sciences Ethical committee (code: IR.MUMS.fm.REC.1396.555). Present study does not contain any study on animals.

Consent to participate:

Written informed consent was obtained from all study participants or their parents.

Consent for publication:

All authors are agree to publish the manuscript.

References

1. Braman SS (2006) The global burden of asthma. Chest 130(1):4S–12S
2. Zahran HS, Bailey CM, Damon SA, Garbe PL, Breysse PN (2018) Vital signs: asthma in children—United States, 2001–2016. Morb Mortal Wkly Rep 67(5):149
3. Boutopoulou B, Koupagioti D, Matziou V, Priftis KN, Douros K (2018) Interventions on adherence to treatment in children with severe asthma: a systematic review. Front Pead 6:232
4. Boy HIA, Rutilla AJH, Santos KA, Ty AMT, Alicia IY, Mahboob T et al (2018) Recommended medicinal plants as source of natural products: a review. Digital Chinese Medicine 1(2):131–142
5. Ejtahed HS, Naslaji AN, Mirmiran P, Yeganeh MZ, Hedayati M, Azizi F et al. Effect of camel milk on blood sugar and lipid profile of patients with type 2 diabetes: a pilot clinical trial. International journal of endocrinology and metabolism. 2015;13(1)
6. Shori AB (2015) Camel milk as a potential therapy for controlling diabetes and its complications: A review of in vivo studies. Journal of food drug analysis 23(4):609–618
7. Mohammaddin A, Rohra DK, Mortaja S, Abanmi S, Al Saati O, Cahusac PM et al (2018) Effects of camel milk in dyslipidaemia: A randomised clinical trial. Int Dairy J 84:79–84
8. Al-Ayadhi LY, Elamin NE. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). Evidence-Based Complementary and Alternative Medicine. 2013;2013
9. Shabo Y, Yagil R (2005) Etiology of autism and camel milk as therapy. International Journal on Disability Human Development 4(2):67
10. Gul W, Farooq N, Anees D, Khan U, Rehan F (2015) Camel milk: a boon to mankind. Int J Res Stud Biosci 3:23–29
11. Kaskous S. Importance of camel milk for human health. Emirates Journal of Food and Agriculture. 2016:158–63
12. Zibaee S (2015) Nutritional and therapeutic characteristics of camel milk in children: a systematic review. Electronic physician 7(7):1523
13. Ravaghi M, Yousefi M, Hosseini SM, Zibaee S, Feyzabadi Z, Salari R (2018) Camel milk could be helpful in the treatment of asthma. Traditional Medicine Research 3(6):307
14. Sharma C, Singh C (2014) Therapeutic value of camel milk—a review. Advanced Journal of Pharmacie Life Science Research 2(3):7–13
15. Abrahaley A, Leta S (2018) Medicinal value of camel milk and meat. Journal of applied animal research 46(1):552–558
16. Smit AJ (2004) Medicinal and pharmaceutical uses of seaweed natural products: a review. J Appl Phycol 16(4):245–262
17. Kelly JP, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA (2005) Recent trends in use of herbal and other natural products. Arch Intern Med 165(3):281–286
18. Shabo Y, Barzel R, Margoulis M, Yagil R (2005) Camel milk for food allergies in children. IMAJ-RAMAT GAN- 7(12):796
19. Kula J (2016) Medicinal values of camel milk. Int J Vet Sci Res 2(1):018–25
20. Bashir S, Al-Ayadhi LY (2014) Effect of camel milk on thymus and activation-regulated chemokine in autistic children: double-blind study. Pediatr Res 75(4):559–563
21. Ravaghi M, Yousefi M, Attaran D, Zibaee S, Salari R, Moghaddam MD et al. Evaluation of the effect of camel milk in comparison with standard medicinal therapy on asthma patients: a parallel clinical trial. Electronic physician. 2019;11(1)
22. Ehlayel M, Bener A, Abu Hazeima K, Al-Mesaifri F. Camel milk is a safer choice than goat milk for feeding children with cow milk allergy. International Scholarly Research Notices. 2011;2011
23. Yoganandi J, Mehta BM, Wadhwani K, Darji V, Aparnathi K (2014) Evaluation and comparison of camel milk with cow milk and buffalo milk for gross composition. Journal of Camel Practice Research 21(2):259–265
24. Yoganandi J, Mehta BM, Wadhwani K, Darji V, Aparnathi dK (2014) Comparison of physico-chemical properties of camel milk with cow milk and buffalo milk. Journal of Camel Practice Research 21(2):253–258
25. Konuspayeva G, Faye B, Loiseau G, Levieux D (2007) Lactoferrin and immunoglobulin contents in camel's milk (Camelus bactrianus, Camelus dromedarius, and Hybrids) from Kazakhstan. J Dairy Sci 90(1):38–46
26. El-Hatmi H, Jrad Z, Salhi I, Aguibi A, Nadri A, Khorchani T. Comparison of composition and whey protein fractions of human, camel, donkey, goat and cow milk. Mljekarstvo: časopis za unapređenje proizvodnje i prerade mlijeka. 2015;65(3):159–67

27. Lee S-H, Ban G-Y, Kim S-C, Chung C-G, Lee H-Y, Lee J-H et al (2020) Association between primary immunodeficiency and asthma exacerbation in adult asthmatics. Korean J Intern Med 35(2):449

28. Urm S-H, Yun HD, Fenta YA, Yoo KH, Abraham RS, Hagan J et al, editors. Asthma and risk of selective IgA deficiency or common variable immunodeficiency: a population-based case-control study. Mayo Clinic Proceedings; 2013: Elsevier

29. Mudgil P, Baby B, Ngoh Y-Y, Kamal H, Vijayan R, Gan C-Y et al (2019) Molecular binding mechanism and identification of novel anti-hypertensive and anti-inflammatory bioactive peptides from camel milk protein hydrolysates. LWT 112:108193

30. Arab HH, Salama SA, Abdelghany TM, Omar HA, Arafa E-SA, Alrobaian MM et al (2017) Camel milk attenuates rheumatoid arthritis via inhibition of mitogen activated protein kinase pathway. Cell Physiol Biochem 43(2):540–552

31. Mati A, Senoussi-Ghezali C, Zennia SSA, Almi-Sebbane D, El-Hatmi H, Girardet J-M (2017) Dromedary camel milk proteins, a source of peptides having biological activities–A review. Int Dairy J 73:25–37

32. Ismael AB, Abd El Hafez SM, Mahmoud MB, Elaraby A-KA, Hassan HM (2013) Development of new strategy for non-antibiotic therapy: Dromedary camel lactoferrin has a potent antimicrobial and immunomodulator effects. Advances in Infectious Diseases 3(04):231

33. Zhu W-W, Kong G-Q, Ma M-M, Li Y, Huang X, Wang L-P et al (2016) Camel milk ameliorates inflammatory responses and oxidative stress and downregulates mitogen-activated protein kinase signaling pathways in lipopolysaccharide-induced acute respiratory distress syndrome in rats. J Dairy Sci 99(1):53–56

Figures
Figure 1

CONSORT flow diagram of the study